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Systemic hypertension and atrial fibrillation (AF) are related.1 Beyond sharing many similar epidemiological 
and pathophysiological features, hypertension is a major risk 
factor for developing AF,1 whereas the history of hypertension 
in the context of AF is associated with an increased risk for 
thromboembolic events.2 Furthermore, the presence of uncon-
trolled blood pressure in patients with AF is associated with an 
increased risk for hemorrhagic stroke,3 major bleeding,4,5 and 
intracranial hemorrhage.5
In the general population, greater blood pressure vari-
ability, defined as systolic blood pressure (SBP)–visit-to-visit 
variability (VVV), is related to a higher risk for cardiovascular 
and cerebrovascular events and with cardiovascular and all-
cause death.6,7 No specific data have been reported about the 
association between SBP-VVV and AF in determining major 
adverse clinical events (ie, stroke, major bleeding, and cardio-
vascular and all-cause death).
In addition, one of the strongest predictors of all major 
adverse events in anticoagulated patients with AF is quality 
of oral anticoagulation control, expressed as individual time 
in therapeutic range (TTR) or percentage of international nor-
malized ratio (INR) in range (PINRR).8–10 No reports have 
explored any relationship between SBP-VVV and quality of 
anticoagulation control.
The aims for this study were (1) to describe the relation-
ship between SBP-VVV and quality of anticoagulation con-
trol, expressed as TTR and PINRR and (2) to analyze any 
association between SBP-VVV and major adverse clinical 
outcomes in patients with AF. These analyses were inves-
tigated as a post hoc ancillary study to the AFFIRM trial 
(Atrial Fibrillation Follow-Up Investigation of Rhythm 
Management), which compared a rate-control versus a 
rhythm-control strategy for the clinical management of 
patients with AF.
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Methods
The AFFIRM trial was a prospective randomized trial, conducted 
by the US National Heart, Lung, and Blood Institute. The study 
protocol and the principal trial results have been described in detail 
elsewhere.11,12 The mean duration of follow-up was 3.5 years. 
Institutional review board for every institution approved study pro-
tocol. All patients entered the study after written informed consent. 
The study was performed according to the European Union Note 
for Guidance on Good Clinical Practice CPMP/ECH/135/95 and the 
Declaration of Helsinki.
For the current analyses, all patients with available data on SBP 
at baseline and with at least 4 other measurements during follow-
up were selected. Blood pressure measurement was performed at 
baseline visit and at every follow-up visit, according to the protocol-
defined schedule (at 2, 4, 8, and 12 months and then every 4 months 
after enrollment11). SBP measurements were performed according to 
normal standard procedures, and no specific procedures were recom-
mended from the study protocol. SBP was defined as controlled at 
baseline when ≤140 mm Hg. SBP-VVV was defined according to the 
SD of mean SBP during follow-up for every patient. According to 
the SBP-SD, patients were categorized in quartiles (1st, <10.09; 2nd, 
10.09–13.85; 3rd, 13.86–17.33; and 4th, ≥17.34 mm Hg).
Thromboembolic risk was defined according to the CHA2DS2-
VASc (congestive heart failure, hypertension, age ≥75 years, diabe-
tes mellitus, stroke/transient ischemic attack, vascular disease, age 
65–74 years, sex category) risk score.13 Low-risk patients were de-
fined as those men with a CHA2DS2-VASc score =0 or women with a 
CHA2DS2-VASc =1; moderate risk was defined as male patients with 
a CHA2DS2-VASc score =1; high risk was defined as patients with a 
CHA2DS2-VASc score ≥2.14
Quality of Anticoagulation Control
Quality of anticoagulation control was assessed according TTR and 
PINRR calculated from INR values retrieved from the follow-up 
forms filled by any physician during the planned follow-up visits at 
2, 4, 8, and 12 months and then every 4 months, after enrollment.11
TTR was calculated according to Rosendaal interpolation meth-
od.15 TTR was calculated for all the patients who qualified for the 
following conditions: (1) at least 1 year of INR observations; (2) at 
least 4 available INR measurements; (3) interval between 2 observa-
tions ≤1 year; (4) in case of 2 INR observation periods of at least 
1 year, separated each other >1 year, the longest one was consid-
ered for calculation; and (5) in the case that 2 INR observation peri-
ods occurred for the same time length, the closest one to the end of 
study was considered for calculation. PINRR was calculated, for all 
patients qualifying for TTR calculation, as the overall percentage of 
INR measurements found during the entire follow-up within the TTR 
between 2 and 3.
Outcomes
Based on the study design, all investigators reported major adverse 
event occurrence at site level, through the follow-up form, providing 
all available clinical details.11 Outcomes of interest were (1) stroke, 
(2) major bleeding, (3) cardiovascular death, (4) all-cause death, and 
(5) a composite outcome of stroke/major bleeding/cardiovascular 
death. A central adjudication committee originally evaluated all the 
recorded events and classified all the death events.
Statistical Analysis
All continuous variables were expressed as mean and SD or median 
and interquartile range (IQR) and compared accordingly with 1-way 
ANOVA or Kruskal–Wallis 1-way ANOVA test. Categorical variables, 
expressed as counts and percentages, were compared with the χ2 test. 
A linear regression model was performed to establish the relationship 
of continuous SBP-SD with TTR and PINRR. A regression model 
was performed and adjusted for congestive heart failure, hypertension, 
age, sex, diabetes mellitus, stroke/transient ischemic attack, myocar-
dial infarction, peripheral arterial disease. A logistic regression model 
was also drafted to establish the relationship between SBP-SD as a 
continuous variable and SBP-SD quartiles with TTR and PINRR at 
progressively lower cut-offs (>70%, ≤65%, and ≤60%). The logistic 
model was adjusted for the same variables as above.
Kaplan–Meier curves for all major adverse clinical outcomes 
considered, according to SBP-SD quartiles, were drafted. Survival 
distributions were compared using the log-rank test. A Cox regres-
sion analysis was performed to establish whether SBP quartiles and 
SBP-SD as a continuous variable were independently associated with 
increased risk for all major adverse clinical outcomes considered. For 
every outcome, for SBP quartiles and continuous SBP-SD, 2 distinct 
Cox models were performed. In the first model, the analysis was ad-
justed for use of warfarin, TTR, hepatic/renal disease, pulmonary 
disease, randomized treatment, and CHA2DS2-VASc. In the second 
model, the analysis was adjusted for use of warfarin, TTR, hepatic/
renal disease, pulmonary disease, randomized treatment, congestive 
heart failure, hypertension, age, sex, diabetes mellitus, stroke/tran-
sient ischemic attack, myocardial infarction, and peripheral arterial 
disease. Several sensitivity analyses evaluated association between 
SBP quartiles and the composite outcome for (1) patients with no 
history of hypertension at baseline; (2) patients with SBP controlled, 
defined as <140 mm Hg, at baseline; (3) elderly patients (ie, ≥75 
years); and (4) patients with high thromboembolic risk. A 2-sided P 
value <0.05 was considered statistically significant. All analyses were 
performed using SPSS v. 24.0 (IBM, NY).
Results
Among 4060 patients enrolled in the original cohort, 3843 
(94.7%) were available for the current analysis. Median 
(IQR) age was 71 (65–76) years, with 1496 (38.9%) women. 
Overall, median (IQR) CHA2DS2-VASc was 3 (2–4). At base-
line median (IQR) SBP was 132 (120–150) mm Hg, whereas 
median (IQR) diastolic blood pressure was 78 (70–84) mm Hg. 
SBP was controlled in 2532 (65.9%) patients. During the 
entire follow-up period, median (IQR) SBP was 135.14 
(125.86–144.44) mm Hg, whereas median (IQR) SBP-SD was 
14.49 (±4.90) mm Hg. TTR and PINRR were available for 
3169 (82.5%) patients. Median (IQR) TTR was 67.9% (51.5–
81.0), whereas median (IQR) PINRR was 62.5% (50.0–76.9).
Baseline characteristics according to SBP-SD quartiles 
are reported in Table 1. Across the quartiles, the median age 
and the proportion of female patients was progressively higher 
(both P<0.001). Baseline SBP and diastolic blood pressure 
were progressively higher with increasing quartiles (P=0.001 
and P<0.001, respectively). The main cardiovascular risk fac-
tors (hypertension and diabetes mellitus) were progressively 
more prevalent across the quartiles (P<0.001 and P=0.013, 
respectively). Patients in 3rd and 4th quartiles had more cor-
onary artery disease (P=0.010), whereas patients in the 4th 
quartile were more likely diagnosed with peripheral arterial 
disease (8.9%) and congestive heart failure (25.3%; P=0.014 
and P<0.001, respectively). CHA2DS2-VASc score was pro-
gressively higher from the 1st to 4th quartile (P<0.001), as 
was the proportion at higher thromboembolic risk (P<0.001).
Despite no difference in use of aspirin and warfarin across 
quartiles, patients in the 4th quartile reported a higher preva-
lence of polypharmacy (45.8%; P<0.001). Both median (IQR) 
TTR and PINRR were progressively lower across quartiles, 
being lowest in the 4th quartile (P<0.001 for both).
SBP-VVV and Quality of Anticoagulation Control
The final adjusted linear regression model found that SBP-SD 
was inversely associated with TTR (standardized beta, 
−0.073; t, −4.142; P<0.001). Indeed, SBP-SD was progres-
sively lower according to increasing TTR (P<0.001; Figure 1, 
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top) and with increasing TTR deciles (P<0.001; Figure 1, bot-
tom). Similarly, SBP-SD was found to be inversely associated 
with PINRR (standardized beta, −0.070; t, −3.959; P<0.001).
In the final logistic regression model (Tables 2 and 3) com-
pared with patients in the 1st quartile, those in 4th quartile 
had a significant inverse association with TTR >70% (odds 
ratio, 0.75; 95% confidence interval [CI], 0.61–0.92), whereas 
patients in the 3rd and 4th quartiles were significantly asso-
ciated with TTR ≤65% (P=0.014 and P<0.001, respectively, 
for 3rd and 4th quartiles) and TTR ≤60% (both P<0.001). 
Continuous SBP-SD was inversely associated with TTR >70% 
(odds ratio, 0.98; 95% CI, 0.96–0.99 per mm Hg) and directly 
associated with TTR ≤65% and TTR ≤60% (both P<0.001). 
Similar results were found for PINRR (Tables 2 and 3).
Follow-Up and Survival Analysis
After a median (IQR) follow-up of 3.6 (2.7–4.6) years, there 
were 149 (3.9%) strokes, 248 (6.5%) major bleeds, 258 
Table 1. Baseline Characteristics According to Systolic Blood Pressure SD Quartiles
Characteristics
1st Quartile  
(<10.09*) N=963
2nd Quartile  
(10.09–13.85*) N=959
3rd Quartile  
(13.86–17.33*) N=962
4th Quartile  
(≥17.34*) N=959 P Value
Age, y, median (IQR) 70 (64–75) 71 (65–76) 71 (65–76) 71 (66–77) <0.001
BMI, kg/m2, median (IQR) 2387 28.2 (24.8–31.9) 27.9 (24.7–31.9) 28.7 (25.4–32.1) 27.7 (24.7–31.5) 0.136
Baseline SBP, mm Hg, median (IQR) 130 (120–140) 132 (120–148) 138 (121–150) 140 (122–156) 0.001
Baseline DBP, mm Hg, median (IQR) 76 (70–80) 78 (70–82) 79 (70–84) 80 (70–86) <0.001
Female sex, n (%) 329 (34.2) 353 (36.8) 387 (40.2) 427 (44.5) <0.001
Minority, n (%) 83 (8.6) 92 (9.6) 114 (11.9) 131 (13.7) 0.002
Hypertension, n (%) 578 (60.0) 646 (67.4) 732 (76.1) 776 (80.9) <0.001
Diabetes mellitus, n (%) 169 (17.5) 177 (18.5) 198 (20.6) 221 (23.0) 0.013
Smoking habit, n (%) 116 (12.0) 102 (10.6) 126 (13.1) 122 (12.7) 0.365
Coronary artery disease, n (%) 345 (35.8) 337 (35.1) 376 (39.1) 400 (41.7) 0.010
Myocardial infarction, n (%) 156 (16.2) 149 (15.5) 172 (17.9) 183 (19.1) 0.155
Peripheral arterial disease, n (%) 52 (5.4) 57 (5.9) 64 (6.7) 85 (8.9) 0.014
Stroke/TIA, n (%) 130 (13.5) 115 (12.0) 130 (13.5) 128 (13.3) 0.713
Congestive heart failure, n (%) 214 (22.2) 170 (17.7) 234 (24.3) 243 (25.3) <0.001
Valvular heart disease, n (%) 124 (12.9) 104 (10.8) 115 (12.0) 126 (13.1) 0.408
Hepatic/renal disease, n (%) 44 (4.6) 40 (4.2) 60 (6.2) 62 (6.5) 0.054
Pulmonary disease, n (%) 143 (14.8) 118 (12.3) 150 (15.6) 139 (14.5) 0.196
First AF episode, n (%) 340 (36.2) 302 (32.7) 312 (33.6) 347 (37.5) 0.107
Randomized treatment, n (%) <0.001
  Rate control 533 (55.3) 514 (53.6) 477 (49.6) 396 (41.3)  
  Rhythm control 430 (44.7) 445 (46.4) 485 (50.4) 563 (58.7)  
Use of aspirin, n (%) 262 (27.2) 240 (25.0) 240 (24.9) 269 (28.1) 0.304
Use of warfarin, n (%) 824 (85.6) 811 (84.6) 827 (86.0) 801 (83.5) 0.443
TTR%, median (IQR) 3169 69.3 (54.2–81.3) 70.2 (55.2–82.8) 66.7 (50.9–80.9) 63.6 (46.4–79.0) <0.001
PINRR%, median (IQR) 3169 64.3 (50.0–77.8) 66.7 (50.0–77.8) 62.5 (50.0–75.0) 60.0 (45.5–73.8) <0.001
Polypharmacy, n (%) 358 (37.3) 318 (33.2) 409 (42.6) 439 (45.8) <0.001
CHA
2
DS
2
-VASc, median (IQR) 3 (2–4) 3 (2–4) 3 (2–4) 3 (2–4) <0.001
CHA
2
DS
2
-VASc, mean (SD) 2.71 (1.40) 2.80 (1.33) 3.04 (1.32) 3.30 (1.41) <0.001
Thromboembolic risk, n (%)     <0.001
  Low risk 22 (2.3) 8 (0.8) 2 (0.2) 5 (0.5)  
  Moderate risk 187 (19.4) 152 (15.8) 118 (12.3) 87 (9.1)  
  High risk 754 (78.3) 799 (83.3) 842 (87.5) 867 (90.4)  
AF indicates atrial fibrillation; BMI, body mass index; CHA
2
DS
2
-VASc, congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient 
ischemic attack, vascular disease, age 65–74 years, sex category; DBP, diastolic blood pressure; IQR, interquartile range; PINRR, percentage of international normalized 
ratio range; SBP, systolic blood pressure; TIA, transient ischemic attack; and TTR, time in therapeutic range.
*Expressed as mm Hg.
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(6.7%) cardiovascular deaths, and 495 (12.9%) all-cause 
deaths. Accordingly, 560 (14.6%) composite outcome events 
were recorded.
According to SBP-SD quartiles (Table 4), rates of stroke 
and major bleeding progressively increased from the 1st to 4th 
quartile (both P<0.001). Also, patients in the 3rd and 4th quar-
tiles had the highest rate for cardiovascular death (P=0.005) and 
all-cause death (P<0.001). The composite outcome of stroke/
major bleeding/cardiovascular death progressively increased 
from the 1st (10.8%) to 4th quartile (20.8%; P<0.001).
Kaplan–Meier curves (Figure 2) demonstrated that 
patients in 3rd and 4th quartiles had progressively higher risk 
for stroke (log-rank, 20.024; P<0.001), major bleeding (log-
rank, 48.322; P<0.001), and cardiovascular death (log-rank, 
11.985; P=0.007; Figure 2A through 2C). Patients in the 4th 
quartile had the highest risk for all-cause death (log-rank, 
21.333; P<0.001; Figure 2D). For the occurrence of the com-
posite outcome, patients in 3rd and 4th quartiles had the high-
est risk (log-rank, 49.929; P<0.001; Figure 3).
Multivariate Analyses
A final forward Cox multivariate regression (Table 5) con-
firmed that patients in the 3rd and 4th quartiles had an inde-
pendent increase in risk for stroke (hazard ratio [HR], 1.85; 
95% CI, 1.02–3.35 and HR, 2.33; 95% CI, 1.30–4.16, respec-
tively) and major bleeding (HR, 1.92; 95% CI, 1.18–3.15 
and HR, 2.88; 95% CI, 1.79–4.61, respectively). SBP-SD 
as a continuous variable was associated with an increased 
Figure 1. Systolic blood pressure (SBP)-SD according to quality of anticoagulation control indexes. Values are expressed as median 
(interquartile range). Top, Time in therapeutic range (TTR); bottom, percentage of international normalized ratio in range (PINRR).
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risk for both outcomes (P=0.002 for stroke and P<0.001 for 
major bleeding).
Despite an increase in risk of cardiovascular death for 
SBP-SD as a continuous variable (P=0.010), SBP-SD quartiles 
were not independently associated with cardiovascular death 
(Table 5). Conversely, patients in 4th quartile had an indepen-
dent increase in risk for all-cause death (HR, 1.38; 95% CI, 
1.00–1.91), which was also evident for SBP-SD as a continu-
ous variable (P<0.001). The risk of the composite outcome was 
increased for patients in 3rd and 4th quartiles (HR, 1.55; 95% CI, 
1.15–2.09 and HR, 1.94; 95% CI, 1.45–2.60). An increased risk 
was confirmed for SBP-SD as a continuous variable (P<0.001).
Sensitivity Analyses
The 4th quartile of SBP-SD was associated with an increased 
risk of stroke/major bleeding/cardiovascular death, in patients 
with no history of hypertension (P=0.010) and in elderly 
patients (P=0.005; Figure 4). The 3rd and 4th quartiles of 
SBP-SD were associated with an increased risk of composite 
outcome in patients with controlled SBP at baseline (P=0.014 
and P<0.001, respectively) and in those at high thromboem-
bolic risk (P=0.009 and P<0.001, respectively).
We performed sensitivity analyses with a logistic regres-
sion analysis for quality of anticoagulation control indexes, 
and second, a Cox regression analysis for major adverse 
outcomes, including the use of aspirin and polypharmacy 
as covariates. These did not affect significantly our results 
(data not shown).
Discussion
In this post hoc subgroup analysis from the AFFIRM trial, we 
demonstrate for the first time in patients with AF that SBP-
VVV (expressed as SBP-SD) is associated with quality of 
anticoagulation control and with major adverse clinical events.
Specifically, we show an inverse linear association 
between increasing SBP-SD and TTR, as well as PINRR. 
Second, increasing SBP-VVV was independently associated 
with an increased risk for stroke, major bleeding, and the 
composite outcome of stroke/major bleeding/cardiovascular 
death. Third, increasing SBP-SD quartiles were associated 
with increased risk for the composite outcome even in specific 
subgroups, such as patients with no history of hypertension, 
elderly patients, patients with controlled SBP at baseline, and 
patients at high thromboembolic risk.
As far as we are aware, no previous data linked SBP-VVV 
and quality of anticoagulation control. Quality of anticoagu-
lation control is a key determinant of major adverse clinical 
events in patients with AF.8 There is an inverse independent 
association between TTR and both thromboembolic, as well 
as bleeding outcomes.8 Indeed, several studies have reported 
that TTR is significantly associated with adverse outcomes 
in specific subgroups, including patients with chronic kidney 
Table 2. Logistic Regression Analysis for Quality of Anticoagulation Control Indexes
SBP-VVV
Time in Therapeutic Range
TTR>70%* TTR≤65%* TTR≤60%*
OR 95% CI P value OR 95% CI P value OR 95% CI P value
1st quartile (ref) … … … … … … … … …
2nd quartile 1.07 0.88–1.31 0.481 0.96 0.78–1.17 0.679 0.95 0.77–1.18 0.660
3rd quartile 0.86 0.71–1.05 0.145 1.28 1.05–1.57 0.014 1.25 1.01–1.53 0.036
4th quartile 0.75 0.61–0.92 0.006 1.54 1.26–1.89 <0.001 1.54 1.25–1.90 <0.001
SBP-SD (per mm Hg) 0.98 0.96–0.99 0.001 1.04 1.02–1.05 <0.001 1.04 1.02–1.05 <0.001
CI indicates confidence interval; INR, international normalized ratio; OR, odds ratio; PINRR, percentage of INR in range; SBP, systolic blood pressure; TTR, time in 
therapeutic range, and VVV, visit-to-visit variability.
*Adjusted for congestive heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic attack, myocardial infarction, peripheral arterial disease, 
and sex.
Table 3. Logistic Regression Analysis for Quality of Anticoagulation Control Indexes
SBP-VVV
Percentage of INR in Range
PINRR>70%* PINRR≤65%* PINRR≤60%*
OR 95% CI P value OR 95% CI P value OR 95% CI P value
1st quartile (ref) … … … … … … … … …
2nd quartile 1.09 0.89–1.34 0.386 0.942 0.77–1.15 0.552 0.98 0.80–1.20 0.864
3rd quartile 0.81 0.66–0.99 0.042 1.24 1.02–1.51 0.033 1.33 1.09–1.62 0.005
4th quartile 0.72 0.58–0.89 0.003 1.44 1.17–1.76 0.001 1.54 1.26–1.89 <0.001
SBP-SD (per mm Hg) 0.97 0.95–0.98 <0.001 1.03 1.02–1.05 <0.001 1.04 1.02–1.06 <0.001
CI indicates confidence interval; INR, international normalized ratio; OR, odds ratio; PINRR, percentage of INR in range; SBP, systolic blood pressure; TTR, time in 
therapeutic range, and VVV, visit-to-visit variability.
*Adjusted for congestive heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic attack, myocardial infarction, peripheral arterial disease, 
and sex.
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disease16 or obesity,17 even independently of sex.18 Similarly, 
PINRR is a strong and independent predictor of outcomes on 
long-term follow-up.10
We could hypothesize that the strong relationship between 
SBP-SD and measures of quality of anticoagulation con-
trol in our study could be an indirect expression of overall 
patients’ adherence to therapy. Indeed, the ALLHAT trial 
(Antihypertensive and Lipid-Lowering Treatment to Prevent 
Heart Attack) showed that patients nonadherent to blood pres-
sure pharmacological treatments had higher blood pressure 
VVV19; furthermore, those patients who improved adherence 
throughout follow-up had a significant reduction of blood 
pressure VVV, whereas nonadherent patients reported an 
increase in blood pressure VVV.19 In an observational cohort 
of AF anticoagulated patients, poor adherence to medications, 
reported as a visual self-reported scale, was associated with 
poor anticoagulation control based on TTR.20 Also, the use of 
educational programmes designed to improve patient adher-
ence to prescription medication is associated with improved 
TTR levels.21 We can also speculate that strategies aimed to 
improve patients’ adherence and management of medications, 
enabling patients to understand, share, and follow physicians’ 
recommendations could improve both SBP variability and 
the quality of anticoagulation control. In addition, we could 
hypothesize that relationship between SBP-VVV and quality 
of anticoagulation control could simply reflect an overall bet-
ter quality of care, both related to physicians and healthcare 
systems. Given that our data were derived from a randomized 
controlled trial, this confounding aspect should be limited.
Hypertension, defined as history of hypertension at the 
beginning of observation, is associated with an increased risk of 
adverse events in patients with AF.1,2 A subgroup analysis from the 
ARISTOTLE trial (Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation) found that clinical 
history of hypertension was associated with an increased risk of 
thromboembolic events (HR, 1.24; 95% CI, 1.03–1.49),3 whereas 
an analysis from the RE-LY (Randomized Evaluation of Long-
Term) anticoagulation therapy trial documented an increased risk 
for major bleeding (HR, 1.25; 95% CI, 1.06–1.46).4
Beyond history of hypertension per se, blood pressure 
VVV is a potent predictor of outcomes in several clinical sce-
narios. Despite a wide variability in assessment and reporting, 
blood pressure VVV results in a relative risk increase ranging 
from 12% to 34% for incident cardiovascular disease, stroke, 
Figure 2. Kaplan–Meier curves for major clinical adverse events. A, Stroke; (B) major bleeding; (C) cardiovascular (CV) death; (D) all-cause 
death; grey dashed line: 1st quartile; black dashed line, 2nd quartile; grey solid line, 3rd quartile; black solid line, 4th quartile.
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cardiovascular death, and all-cause death.7 Recently, a large 
study of >2.5 million subjects conducted among US veterans 
reported that increasing quartiles of SBD-SD were associated 
with increasing risk for incident cardiovascular disease, stroke, 
all-cause death, and incident end-stage renal disease.6 Our data 
confirm that higher SBP-VVV is a strong predictor of stroke and 
death even in AF subjects. In the context of AF, SBP-VVV is 
also a powerful predictor of major bleeding, irrespective of oral 
anticoagulation treatment and quality of anticoagulation control.
Beyond adherence to medications, possible mechanistic rea-
sons for the association between SBP-VVV and major adverse 
events have been proposed. For example, subclinical athero-
sclerosis,22–24 increased intima-media thickness,23 and endothe-
lial dysfunction25–27 have been associated with SBP variability. 
These relationships are evident, even in high-risk (eg, diabetic) 
patients,24 the elderly,23 and nonhypertensive subjects.26
In patients with AF, no data thus far have been reported 
about the relationship between SBP-VVB and outcomes, but 
some proxy measures of blood pressure long-term control have 
been studied in relation to outcomes. In a substudy from an 
observational Japanese registry, blood pressure measured at 
the time of outcome occurrence or at the end of observation 
was taken as a measure of blood pressure control over time.5 
In this cohort, patients among the 4th quartile of SBP had an 
increased risk for both thromboembolic (odds ratio, 2.88; 95% 
CI, 1.75–4.74) and major bleeding (odds ratio, 1.61; 95% CI, 
1.02–2.53) events, compared with the 1st quartile.5 A further 
refined model, adjusted according to predicted risk of bleeding, 
demonstrated that patients in the 4th quartile of SBP had an 
increased risk for intracranial hemorrhage but not major bleed-
ing.5 In the study by Rao et al,3 uncontrolled blood pressure 
over time, defined as a SBP ≥140 mm Hg or diastolic blood 
pressure ≥90 mm Hg at any time during follow-up observa-
tion was associated with an increased risk for thromboembolic 
events (HR, 1.53; 95% CI, 1.25–1.86) and major/clinically rel-
evant nonmajor bleeding (HR, 1.14; 95% CI, 1.01–1.28). Our 
study reports for the first time that a reliable direct measure of 
SBP-VVV is strongly associated with stroke, major bleeding, 
and mortality outcomes. Moreover, we show that an associa-
tion between SBP-VVV and risk of the adverse outcomes is 
consistent irrespective of elderly age, blood pressure history, 
blood pressure control, and thromboembolic risk strata.
Our data suggest that strict and consistent SBP control is 
highly desirable in patients with AF. Further, more intensive 
Figure 3. Kaplan–Meier curves for 
composite outcome. Grey dashed line, 
1st quartile; black dashed line, 2nd 
quartile; grey solid line, 3rd quartile; black 
solid line, 4th quartile.
Table 4. Major Adverse Clinical Outcomes According to Systolic Blood Pressure SD Quartiles
Outcomes
1st Quartile  
(<10.09*) N=963
2nd Quartile  
(10.09–13.85*) N=959
3rd Quartile  
(13.86–17.33*) N=962
4th Quartile  
(≥17.34*) N=959 P Value
Stroke, n (%) 24 (2.5) 29 (3.0) 37 (3.8) 59 (6.2) <0.001
Major bleeding, n (%) 38 (3.9) 41 (4.3) 65 (6.8) 104 (10.8) <0.001
CV death, n (%) 55 (5.7) 50 (5.2) 67 (7.0) 86 (9.0) 0.005
All-cause death, n (%) 106 (11.0) 105 (10.9) 117 (12.2) 167 (17.4) <0.001
Stroke/major bleeding/CV death, n (%) 104 (10.8) 107 (11.2) 150 (15.6) 199 (20.8) <0.001
CV indicates cardiovascular.
*Expressed as mm Hg.
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Table 5. Cox Regression Analysis for Major Adverse Events
Outcomes
Model 1* Model 2†
HR 95% CI P Value HR 95% CI P Value
Stroke
  SBP-SD quartiles       
   1st quartile (ref) … … … … … …
   2nd quartile 1.42 0.76–2.67 0.272 1.42 0.76–2.66 0.276
   3rd quartile 1.80 1.00–3.26 0.052 1.85 1.02–3.35 0.042
   4th quartile 2.21 1.23–3.97 0.008 2.33 1.30–4.16 0.004
  SBP-SD (per mm Hg) 1.06 1.02–1.09 0.004 1.06 1.02–1.10 0.002
Major bleeding
  SBP-SD quartiles       
   1st quartile (ref) … … … … … …
   2nd quartile 1.35 0.79–2.28 0.273 1.34 0.79–2.28 0.278
   3rd quartile 1.90 1.16–3.11 0.011 1.92 1.18–3.15 0.009
   4th quartile 2.82 1.75–4.53 <0.001 2.88 1.79–4.61 <0.001
  SBP-SD (per mm Hg) 1.07 1.04–1.10 <0.001 1.08 1.05–1.11 <0.001
CV death
  SBP-SD quartiles       
   1st quartile (ref) … … … … … …
   2nd quartile 0.94 0.60–1.47 0.936 1.00 0.64–1.57 0.996
   3rd quartile 1.01 0.66–1.55 0.965 1.05 0.68–1.60 0.840
   4th quartile 1.12 0.74–1.71 0.585 1.22 0.80–1.87 0.349
  SBP-SD (per mm Hg) 1.03 1.00–1.06 0.034 1.04 1.01–1.07 0.010
All-cause death
  SBP-SD quartiles       
   1st quartile (ref) … … … … … …
   2nd quartile 1.12 0.80–1.57 0.497 1.18 0.85–1.66 0.322
   3rd quartile 1.02 0.73–1.42 0.911 1.08 0.78–1.50 0.650
   4th quartile 1.25 0.91–1.73 0.166 1.38 1.00–1.91 0.048
  SBP-SD (per mm Hg) 1.04 1.02–1.06 <0.001 1.05 1.02–1.07 <0.001
Stroke/major bleeding/CV death
  SBP-SD quartiles       
   1st quartile (ref) … … … … … …
   2nd quartile 1.18 0.86–1.63 0.305 1.22 0.89–1.68 0.225
   3rd quartile 1.52 1.12–2.04 0.006 1.55 1.15–2.09 0.004
   4th quartile 1.87 1.39–2.50 <0.001 1.94 1.45–2.60 <0.001
  SBP-SD (per mm Hg) 1.05 1.03–1.07 <0.001 1.06 1.04–1.08 <0.001
CHA
2
DS
2
-VASc indicates congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, stroke/transient ischemic attack, 
vascular disease, age 65–74 years, sex category; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; and SBP, systolic blood 
pressure.
*Adjusted for use of warfarin, time in therapeutic range, hepatic/renal disease, pulmonary disease, randomized treatment, and 
CHA
2
DS
2
-VASc.
†Adjusted for use of warfarin, time in therapeutic range, hepatic/renal disease, pulmonary disease, randomized treatment, congestive 
heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic attack, myocardial infarction, peripheral arterial disease, 
and sex.
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treatment aimed to achieve lower blood pressure and SBP 
levels is associated with better outcomes during long-term 
follow-up.28 In a recent network meta-analysis of hypertensive 
subjects, the lowest mean achieved SBP (120–124 mm Hg) ver-
sus the highest (≥160 mm Hg) is associated with a larger reduc-
tion of cardiovascular disease and all-cause death.29 Also, in a 
post hoc analysis from 2 large randomized controlled trials of 
antihypertensive medications, the highest mean achieved SBP 
was associated with the highest risk of a composite outcome of 
cardiovascular death, myocardial infarction, stroke, and hospi-
tal admission for heart failure and for all-cause death.30
Limitations
The main limitation of this study is related to the post hoc 
design. Similarly, another major limitation lies in the non-
standardized measurement of blood pressure, which could 
have affected the reproducibility of SBP-VVV measurements 
and has to be considered when interpreting our data. We also 
cannot account for differences in paroxysmal and permanent 
AF because type of AF was not available for this analysis. 
Furthermore, we could not account for medication adherence 
throughout the follow-up period. Also, we could not define 
whether blood pressure measurements accounted for the irreg-
ularity in rhythm at the precise time of actual measurement. 
Conversely, the AFFIRM study is largely known to be a well-
controlled reliable study with adjudicated outcomes.
Perspectives
In a large cohort of patients with AF derived from a random-
ized controlled trial, SBP-VVV is inversely associated with 
anticoagulation control, whereas increasing SBP-VVV is asso-
ciated with a higher of major adverse outcomes. Strategies to 
reduce SBP-VVV, as well as to improve oral anticoagulation 
control, are needed among patients with AF and would help 
reduce major adverse clinical outcomes in patients with AF.
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What Is New?
•	Systolic blood pressure (SBP)–visit-to-visit variability (VVV) was found 
associated with a worse quality of anticoagulation control.
•	A higher SBP-VVV identified patients with a higher risk of major adverse 
events in a large atrial fibrillation cohort.
What Is Relevant?
•	A better management of SBP during a long-term clinical follow-up would 
help improving outcomes in patients with atrial fibrillation.
Summary
SBP-VVV in a large cohort of patients with atrial fibrillation, derived 
from a randomized controlled trial, was found to be associated with 
worse quality of anticoagulation control. An increased SBP-VVV 
was also independently associated with an increased risk of stroke, 
major bleeding, cardiovascular death, and all-cause death during a 
long-term follow-up, beyond advanced age, hypertension history, 
blood pressure control at baseline, and increased thromboembolic 
risk. Interventions to achieve better management of blood pressure 
to obtain a lower SBP-VVV would improve quality of anticoagulation 
control and minimize major clinical outcomes.
Novelty and Significance
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